SCHEMBL7142089

SCHEMBL7142089

Cc1cccc(-c2c[nH]c(-c3ccccc3)n2)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.39
PARP1 P09874 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
NUDT1 P36639 2/20 0.38
POLB P06746 2/20 0.36
ENPP3 O14638 1/20 0.36
ENPP1 P22413 1/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
RAB9A P51151 4/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 3/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 3/20 0.35
NPC1 O15118 2/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7139325 0.89 IDO1 (0.42) TNKSPARP1TNKS2ENPP3ENPP1
SCHEMBL17280162 0.83 IDO1 (0.40) ENPP3ENPP1RAB9AALDH1A1KDM4E
SCHEMBL9957653 0.82 RPS6KA3 (0.42) TNKSPARP1TNKS2POLBRAB9A
SCHEMBL7140298 0.82 ALDH1A1 (0.40) NUDT1RAB9AALDH1A1KDM4EMEN1
SCHEMBL7136950 0.81 NR1H2 (0.43) TNKSPARP1TNKS2ENPP3ENPP1
SCHEMBL29785392 0.80 DCUN1D1 (0.44) PARP1RAB9AALDH1A1KDM4EMEN1
SCHEMBL28813677 0.80 DCUN1D1 (0.44) PARP1RAB9AALDH1A1KDM4EMEN1
SCHEMBL17472957 0.79 POLB (0.37) TNKSPARP1TNKS2POLBRAB9A
SCHEMBL10476801 0.79 ENPP3 (0.45) POLBENPP3ENPP1RAB9AALDH1A1
SCHEMBL31305513 0.79 ENPP3 (0.45) POLBENPP3ENPP1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed
US-5560785-A TREATING SURFACE WITH SOLUTION OF IMIDAZOLE COMPOUND, COPPER COMPOUND, ZINC COMPOUND, STABILIZERS SHIKOKU CHEMICALS CORPORATION (JP) 1996-10-01 US disclosed
US-5498301-A ON A PRINTED WIRING BOARD, HEAT RESISTANT, MOISTURE RESISTANT, A 2-ARYLIMIDAZOLE, CARBOXYLIC ACID, AMMONIA, WATER SHIKOKU CHEMICALS CORPORATION (JP) 1996-03-12 US disclosed
EP-0627499-A1 Agent for treating surfaces of copper and copper alloys SHIKOKU CHEMICALS CORPORATION (JP) 1994-12-07 EP disclosed